Case study: Use of a library of antisense inhibitors for gene functionalization and drug target validation

Drug Discovery Today: TARGETS

Volumn 3, Issue 3, 2004, Pages 117-122

  Marcusson, Eric G ^a   Vincent, Thomas M ^a   Hari, Kumar L ^a   Chiang, MingYi ^a   Dean, Nicholas M ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

antisense; Cell biology; cell based assays; database; Drug Discovery; drug discovery; functional genomics; Genetics; Pharmacology; target validation

Indexed keywords

COMPLEMENTARY DNA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; RECOMBINANT DNA;

BIOAVAILABILITY; CELL BASED GENE THERAPY; CELL CYCLE; CORRELATION ANALYSIS; CROSS COUPLING REACTION; DNA MICROARRAY; DRUG TARGETING; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC SCREENING; GENETIC TRANSFECTION; HUMAN; HUMAN GENOME; IN VITRO STUDY; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TECHNIQUE; VALIDATION PROCESS;

EID: 12344250541     PISSN: 17418372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1741-8372(04)02430-2     Document Type: Review

References (40)

1. Fleischmann R.D, et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 269:1995;496-512
2. Goffeau A, et al. Life with 6000 genes. Science. 274:1996;546-567
3. Consortium. Genome sequence of the nematode C. elegans: a platform for investigating biology. Science. 282:1998;2012-2018
4. Adams M.D, et al. The genome sequence of Drosophila melanogaster. Science. 287:2000;2185-2195
5. Lander E.S, et al. Initial sequencing and analysis of the human genome. Nature. 409:2001;860-921
6. Venter J.C, et al. The sequence of the human genome. Science. 291:2001;1304-1351
7. Katsuma S, Tsujimoto G. Genome medicine promised by microarray technology. Expert Rev. Mol. Diagn. 1:2001;377-382
8. Sanseau P. Impact of human genome sequencing for in silico target discovery. Drug Discov. Today. 6:2001;316-323
9. Kanehisa M, Bork P. Bioinformatics in the post-sequence era. Nat. Genet. 33:(Suppl.):2003;305-310
10. Frazier M.E, et al. Realizing the potential of the genome revolution: the genomes to life program. Science. 300:2003;290-293
11. Chanda S.K, Caldwell J.S. Fulfilling the promise: drug discovery in the post-genomic era. Drug Discov. Today. 8:2003;168-174
12. Johnston P.A. Cellular platforms for HTS: three case studies. Drug Discov. Today. 7:2002;353-363
13. Horrocks C, et al. Human cell systems for drug discovery. Curr. Opin. Drug Discov. Devel. 6:2003;570-575
14. Dean N.M. Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr. Opin. Biotechnol. 12:2001;622-625
15. Lorens J.B, et al. The use of retroviruses as pharmaceutical tools for target discovery and validation in the field of functional genomics. Curr. Opin. Biotechnol. 12:2001;613-621
16. Nuttall M.E. Drug discovery and target validation. Cells Tissues Organs. 169:2001;265-271
17. Bradham C.A, et al. Dominant-negative TAK1 induces c-Myc and G(0) exit in liver. Am. J. Physiol. Gastrointest. Liver Physiol. 281:2001;G1279-G1289
18. Curnock A.P, Ward S.G. Development and characterisation of tetracycline-regulated phosphoinositide 3-kinase mutants: assessing the role of multiple phosphoinositide 3-kinases in chemokine signaling. J. Immunol. Methods. 273:2003;29-41
19. Inamdar M.S. Functional genomics the old-fashioned way: chemical mutagenesis in mice. Bioessays. 23:2001;116-120
20. Kulkarni A.B, et al. Function of cytokines within the TGF-beta superfamily as determined from transgenic and gene knockout studies in mice. Curr. Mol. Med. 2:2002;303-327
21. Zamecnik P.C, Stephenson M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. U. S. A. 75:1978;280-284
22. Bennett C.F. Efficiency of antisense oligonucleotide drug discovery. Antisense Nucleic Acid Drug Dev. 12:2002;215-224
23. Takagi Y, et al. Mechanism of action of hammerhead ribozymes and their applications in vivo: rapid identification of functional genes in the post-genome era by novel hybrid ribozyme libraries. Biochem. Soc. Trans. 30:2002;1145-1149
24. Shi Y. Mammalian RNAi for the masses. Trends Genet. 19:2003;9-12
25. Vacek M, et al. Antisense-mediated redirection of mRNA splicing. Cell. Mol. Life Sci. 60:2003;825-833
26. Bennett C.F, Cowsert L.M. Application of antisense oligonucleotides for gene functionalization and target validation. Curr. Opin. Mol. Ther. 1:1999;359-371
27. Harris M.A, et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res. 32:2004;D258-D261
28. Dean N.M, Griffey R.H. Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 7:1997;229-233
29. Monia B.P. First- and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase. Ciba Found. Symp. 209:1997;107-119
30. Butler M, et al. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes. 51:2002;1028-1034
31. Jang M.S, et al. Notch signaling as a target in multimodality cancer therapy. Curr. Opin. Mol. Ther. 2:2000;55-65
32. Zlobin A, et al. Toward the rational design of cell fate modifiers: notch signaling as a target for novel biopharmaceuticals. Curr. Pharm. Biotechnol. 1:2000;83-106
33. Kyriakis J.M, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81:2001;807-869
34. Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Annu. Rev. Nutr. 22:2002;167-197
35. Lee C.H, et al. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology. 144:2003;2201-2207
36. Dean N.M, McKay R. Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides. Proc. Natl. Acad. Sci. U. S. A. 91:1994;11762-11766
37. Nyce J.W, Metzger W.J. DNA antisense therapy for asthma in an animal model. Nature. 385:1997;721-725
38. Skorski T, et al. Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide. Proc. Natl. Acad. Sci. U. S. A. 91:1994;4504-4508
39. Webb A, et al. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet. 349:1997;1137-1141
40. Yao Z, et al. In vivo inhibition of hepatitis B viral gene expression by antisense phosphorothioate oligodeoxynucleotides in athymic nude mice. J. Viral Hepat. 3:1996;19-22